We are testing a new drug called ALTA2618 for patients with advanced solid tumors that have the AKT1 E17K mutation. The goal is to see how safe it is and how it affects tumor growth.
Health conditions and diseases that the clinical trial is designed to study and treat.
Advanced Solid Tumors with AKT1 E17K Mutation are a type of cancer characterized by the presence of a specific genetic mutation in the AKT1 gene, which can affect tumor growth and response to treatment. This condition often involves various solid tumors and may require specialized treatment approaches.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
